BridgeBio Thinks Its Phase III Limb-Girdle MD Data Could Support Full Approval

 
• By Joseph Haas
  
BridgeBio
With strong Phase III data, BridgeBio hopes to bring its second rare disease drug to market • Source: Shutterstock

More from Clinical Trials

More from R&D